Bone morphogenetic protein-2 blocks MDA MB 231 human breast cancer cell proliferation by inhibiting cyclin-dependent kinase-mediated retinoblastoma protein phosphorylation

Biochemical and Biophysical Research Communications

Volumn 272, Issue 3, 2000, Pages 705-711

  Ghosh Choudhury, Nandini ^a   Woodruff, Kathleen ^a   Qi, Wenbo ^a   Celeste, Anthony ^c   Abboud, Sherry L ^a   Ghosh Choudhury, Goutam ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c Genetics Institute   (United States)

Author keywords

BMP 2; Breast cancer cells; p21; pRb

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN E; DNA; EPIDERMAL GROWTH FACTOR; PROTEIN P21; RETINOBLASTOMA PROTEIN;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 0034674353     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2000.2844     Document Type: Article

References (35)

1. Cailleau R., Mackay B., Young R. K., Reeves W. J. Jr. Tissue culture studies on pleural effusions from breast carcinoma patients. Cancer Res. 34:1974;801-809.
2. Dong X. F., Berthois Y., Martin P. M. Effect of epidermal growth factor on the proliferation of human epithelial cancer cell lines: Correlation with the level of occupied EGF receptor. Anticancer Res. 11:1991;737-743.
3. Pines J. Cyclins, CDKs and cancer. Semin. Cancer Biol. 6:1995;63-72.
4. Sherr C. J. G1 phase progression: Cycling on cue. Cell. 79:1994;551-555.
5. Ohtsubo M., Theodoras A. M., Schumacher J., Roberts J. M., Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol. Cell. Biol. 15:1995;2612-2624.
6. Weinberg R. A. The retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330.
7. Niculescu A. B. 3rd, Chen X., Smeets M., Hengst L., Prives C., Reed S. I. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell. Biol. 18:1998;629-643.
8. Gu Y., Turck C. W., Morgan D. O. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature. 366:1993;707-710.
9. Xiong Y., Hannon G. J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 366:1993;701-704.
10. Wozney J. M. The bone morphogenetic protein family and osteogenesis. Mol. Reprod. Dev. 32:1992;160-167.
11. Hogan B. L. Bone morphogenetic proteins: Multifunctional regulators of vertebrate development. Genes Dev. 10:1996;1580-1594.
12. Katagiri T., Yamaguchi A., Komaki M., Abe E., Takahashi N., Ikeda T., Rosen V., Wozney J. M., Fujisawa-Sehara A., Suda T. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell. Biol. 127:1994;1755-1766.
13. Lyons K. M., Pelton R. W., Hogan B. L. Organogenesis and pattern formation in the mouse: RNA distribution patterns suggest a role for bone morphogenetic protein-2A (BMP-2A). Development. 109:1990;833-844.
14. Kretzschmar M., Liu F., Hata A., Doody J., Massague J. The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes Dev. 11:1997;984-995.
15. Heldin C. H., Miyazono K., ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 390:1997;465-471.
16. Niehrs C. Growth factors. Mad connection to the nucleus. Nature. 381:1996;561-562.
17. Ide H., Yoshida T., Matsumoto N., Aoki K., Osada Y., Sugimura T., Terada M. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res. 57:1997;5022-5027.
18. Nakaoka T., Gonda K., Ogita T., Otawara-Hamamoto Y., Okabe F., Kira Y., Harii K., Miyazono K., Takuwa Y., Fujita T. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. J. Clin. Invest. 100:1997;2824-2832.
19. Ghosh Choudhury G., Kim Y. S., Simon M., Wozney J., Harris S., Ghosh-Choudhury N., Abboud H. E. Bone morphogenetic protein 2 inhibits platelet-derived growth factor- induced c-fos gene transcription and DNA synthesis in mesangial cells. Involvement of mitogen-activated protein kinase. J. Biol. Chem. 274:1999;10897-10902.
20. Ghosh Choudhury G., Jin D. C., Kim Y., Celeste A., Ghosh-Choudhury N., Abboud H. E. Bone morphogenetic protein-2 inhibits MAPK-dependent Elk-1 transactivation and DNA synthesis induced by EGF in mesangial cells. Biochem. Biophys. Res. Commun. 258:1999;490-496.
21. Soda H., Raymond E., Sharma S., Lawrence R., Cerna C., Gomez L., Timony G. A., Von Hoff D. D., Izbicka E. Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units. Anticancer Drugs. 9:1998;327-331.
22. Ghosh Choudhury G., Ghosh-Choudhury N., Abboud H. E. Association and direct activation of signal transducer and activator of transcription 1 alpha by platelet-derived growth factor receptor. J. Clin. Invest. 101:1998;2751-2760.
23. Gong J., Ko T. C., Brattain M. G. Disruption of fibronectin binding to the alpha 5 beta 1 integrin stimulates the expression of cyclin-dependent kinases and DNA synthesis through activation of extracellular signal-regulated kinase. J. Biol. Chem. 273:1998;1662-1669.
24. Kim H., Muller W. J. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp. Cell Res. 253:1999;78-87.
25. Planas-Silva M. D., Weinberg R. A. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol. Cell. Biol. 17:1997;4059-4069.
26. Hauschka P. V. Hall B. K. Bone: The Osteoblasts and Osteocytes. 1990;103-171 CRC, Telford.
27. Wozney J. M., Rosen V. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin. Orthop. 1998;26-37.
28. Moghal N., Sternberg P. W. Multiple positive and negative regulators of signaling by the EGF-receptor. Curr. Opin. Cell Biol. 11:1999;190-196.
29. Jacks T., Weinberg R. A. The expanding role of cell cycle regulators. Science. 280:1998;1035-1036.
30. Halevy O., Novitch B. G., Spicer D. B., Skapek S. X., Rhee J., Hannon G. J., Beach D., Lassar A. B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science. 267:1995;1018-1021.
31. Barbareschi M., Caffo O., Doglioni C., Fina P., Marchetti A., Buttitta F., Leek R., Morelli L., Leonardi E., Bevilacqua G., Dalla Palma P., Harris A. L. p21WAF1 immunohistochemical expression in breast carcinoma: Correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br. J. Cancer. 74:1996;208-215.
32. Waga S., Hannon G. J., Beach D., Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 369:1994;574-578.
33. Zwijsen R. M., Klompmaker R., Wientjens E. B., Kristel P. M., van der Burg B., Michalides R. J. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit. Mol. Cell Biol. 16:1996;2554-2560.
34. Muller H., Helin K. The E2F transcription factors: Key regulators of cell proliferation. Biochim. Biophys. Acta. 1470:2000;M1-M12.
35. Gray-Bablin J., Zalvide J., Fox M. P., Knickerbocker C. J., DeCaprio J. A., Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer. Proc. Natl. Acad. Sci. USA. 93:1996;15215-15220.